Aldeyra Therapeutics, Inc. financial data

Symbol
ALDX on Nasdaq
Location
Lexington, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 27 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 326% % -43%
Debt-to-equity 54% % 65%
Return On Assets -41% % 9.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,182,782 shares 0.79%
Common Stock, Shares, Outstanding 60,162,773 shares 0.86%
Entity Public Float $231,896,127 USD 21%
Common Stock, Value, Issued $60,163 USD 0.86%
Weighted Average Number of Shares Outstanding, Basic 60,056,557 shares 0.96%
Weighted Average Number of Shares Outstanding, Diluted 60,056,557 shares 0.96%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $25,662,855 USD -47%
General and Administrative Expense $9,602,351 USD -19%
Operating Income (Loss) $35,265,206 USD 41%
Nonoperating Income (Expense) $1,418,545 USD -67%
Net Income (Loss) Attributable to Parent $33,846,661 USD 39%
Earnings Per Share, Basic -0.56 USD/shares 40%
Earnings Per Share, Diluted -0.56 USD/shares 40%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $70,041,254 USD 28%
Marketable Securities, Current $15,956,740 USD -64%
Other Assets, Current $755,545 USD
Assets, Current $71,783,456 USD -31%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $275,861 USD 3.3%
Assets $72,059,317 USD -31%
Accounts Payable, Current $158,461 USD -12%
Employee-related Liabilities, Current $4,272,999 USD -1.4%
Accrued Liabilities, Current $6,120,297 USD -49%
Liabilities, Current $27,808,927 USD 49%
Operating Lease, Liability, Noncurrent $0 USD
Liabilities $27,808,927 USD -17%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD -100%
Retained Earnings (Accumulated Deficit) $483,957,253 USD -7.5%
Stockholders' Equity Attributable to Parent $44,250,390 USD -38%
Liabilities and Equity $72,059,317 USD -31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $12,469,699 USD -25%
Net Cash Provided by (Used in) Financing Activities $1,002,810 USD 5413%
Net Cash Provided by (Used in) Investing Activities $7,290,414 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 60,162,773 shares 0.86%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,176,475 USD 90%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70,041,254 USD 28%
Interest Paid, Excluding Capitalized Interest, Operating Activities $416,250 USD -5.4%
Deferred Tax Assets, Valuation Allowance $130,890,968 USD 7.7%
Deferred Tax Assets, Gross $130,966,333 USD 7.7%
Operating Lease, Liability $280,537 USD 3.3%
Depreciation $60,912 USD 0.46%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $33,884,103 USD 39%
Lessee, Operating Lease, Liability, to be Paid $294,557 USD 3.3%
Operating Lease, Liability, Current $280,537 USD 3.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $294,557 USD 3.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.091 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14,020 USD 3.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $75,365 USD -6.7%
Share-based Payment Arrangement, Expense $6,091,413 USD -24%
Interest Expense $2,029,134 USD 7%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%